William Blair Downgrades ARS Pharmaceuticals to Market Perform
Portfolio Pulse from Benzinga Newsdesk
William Blair analyst Tim Lugo has downgraded ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Market Perform.
September 20, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ARS Pharmaceuticals has been downgraded by William Blair from Outperform to Market Perform, which may negatively impact the stock's performance.
Analyst ratings often influence investor sentiment and can impact a stock's price. A downgrade from Outperform to Market Perform suggests that the analyst believes the stock will now perform in line with the market, rather than outperforming it. This could lead to a decrease in demand for the stock, potentially causing its price to fall in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100